On March 15, 2021 Merck (NYSE: MRK), known as MSD outside the United States and Canada, reported that the company will host a virtual investor event to discuss Merck’s broad HIV program and the newly announced collaboration with Gilead Sciences (Press release, Merck & Co, MAR 15, 2021, View Source [SID1234576648]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at View Source Institutional investors and analysts who would like to ask a question during the session, please dial in using the information on the events page and follow the operator’s instructions.